Grail unveils competitive ASCO data from second substudy of CCGA trial
Just a day after the launch of the latest liquid biopsy company, data from Grail show it will be a tight race to develop a multicancer liquid biopsy test for early cancer detection -- and that Grail’s decision to focus on methylation signatures may be paying off.
Grail Inc. (Menlo Park, Calif.) announced data from a second preplanned substudy of the Circulating Cell-free Genome Atlas (CCGA) study showing that across 12 deadly tumor types, the biotech's multicancer blood test had a sensitivity of 76% and accurately predicted the tissue of origin for the cancer, regardless of stage of disease, in 84-92% of cases. The specificity of Grail's plasma cell-free DNA assay was 99%. The data will be presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago Saturday...